BMC updated sleep devices after defect, leaving up to 196 uncertain

Low risk products intended only to support healthy living remain outside strict medical device enforcement. That position was repeated by the Food and Drug Administration in revised guidance published January 6, 2026, and it formed the background to the August 19, 2026 Class I recall of 20,160 BMC Luna G3 APAP Model LG3600 units in the United States.

The paper carries the title General Wellness. Policy for Low Risk Devices. It supersedes the 2019 guidance and maps low risk products that support a healthy lifestyle.

Software functions meant only to maintain or encourage healthy living, with no link to diagnosis, cure, mitigation, prevention or treatment, fall outside the medical device definition under Section 520(o)(1)(B). Non software products with that same purpose receive enforcement discretion, so the agency does not plan to apply requirements under the Federal Food, Drug, and Cosmetic Act.

The policy excludes drugs, biologics, dietary supplements, foods, cosmetics overseen by other FDA Centers and combination products. Non-invasive products that estimate blood pressure for wellness purposes may qualify when the intended use stays strictly focused on wellness and the remaining conditions are satisfied.

A wearable that estimates blood glucose to track nutritional effects may qualify when it is expressly contraindicated for people with diabetes and pre-diabetes. A blood glucose wearable built on minimally invasive microneedle technology remains outside low risk even when its claims speak only of wellness.

Sensor based wellness products lose general wellness status when they recommend particular clinical steps, provide treatment advice, or measure for screening, diagnosis, monitoring or management of disease. They also lose that status when they claim to replace an FDA cleared device or when they mention particular diseases or diagnostic cutoffs.

The Luna G3 APAP recall showed where that boundary continues to hold. BMC Medical Co., Ltd. reported the action on July 15, 2026 after identifying a firmware defect, and FDA listed it as Recall Number Z-2979-2026.

Firmware version G3-2.00.76 could produce an error message and then shut down automatically and stop delivering therapy during high pressure, high respiratory rate and high peak flow. BMC moved firmware to version G3-2.00.77 for 20,160 units held at the United States importers warehouse between October and December 2024, yet later found that potentially as many as 196 units might have missed the update. BMC had received no complaints or serious adverse reports by the September 8, 2026 notice. Whether any units without the upgrade remain in use is not known.

Forecasts suggest further expansion on the wellness side of that line. The North America medical wellness devices market is valued at US$44.4 billion in 2026 and is projected to reach US$71.8 billion by 2033 at a compound annual growth rate of 7.1 percent. The United States is expected to hold 80 percent market share in 2026, while Canada is identified as the fastest growing region.

Diabetic monitoring devices are projected to hold 37 percent of revenue share in 2026, and retail sales are expected to account for more than 62 percent. Consumer grade devices still raise questions over uneven readings relative to hospital grade equipment, along with data privacy concerns.

Attention now turns to whether 2026 retail results align with forecasts, and to how validation limits develop for everyday trackers.